Recombinant Human CLEC9a Fc Chimera Protein, CF Summary
Accession # Q6UXN8
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 200 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
CLEC9A (C-type lectin domain family 9 member A), also known as DNGR-1, is a type II transmembrane glycoprotein member of the C-type lectin superfamily (1). Mature mouse CLEC9A consists of a 35 amino acid (aa) cytoplasmic domain with an ITAM-like motif, a 21 aa transmembrane segment, and a 185 extracellular domain (ECD) that contains a stalk region and one C-type lectin domain (CTLD) (2-4). Within the ECD, human CLEC9A shares 57% aa sequence identity with mouse and rat CLEC9A. Although the CTLD of CLEC9A structurally resembles that of other C-type lectins, it lacks the conserved residues that typically mediate calcium and carbohydrate binding. CLEC9A is expressed as a disulfide-linked homodimer of approximately 50 kDa N-glycosylated subunits (2, 4). Human CLEC9A expression is restricted to a subpopulation of BDCA-3+ conventional dendritic cells (cDC) and CD16- monocytes (2-5). BDCA-3+ cDC are analagous to mouse CD8+ cDC which are specialized in antigenic cross-presentation in complex with MHC class I molecules (6). In mouse, CLEC9A is additionally expressed on plasmacytoid dendritic cells (3, 4). CLEC9A ligation enhances antigen uptake and processing, leading to presentation on MHC class I and cytotoxic T cell (CTL) priming (2-5, 7). Its recognition of filamentous actin in dead cells is important for triggering an immune response to necrotic cell debris (8-10). CLEC9A is also required for the presentation of viral proteins and the subsequent CTL-mediated killing of virus-infected cells (11, 12). CLEC9A signaling triggers activation of the tyrosine kinase Syk (2, 8).
- Kerrigan, A.M. and G.D. Brown (2010) Immunol. Rev. 234:335.
- Huysamen, C. et al. (2008) J. Biol. Chem. 283:16693.
- Caminschi, I. et al. (2008) Blood 112:3264.
- Sancho, D. et al. (2008) J. Clin. Invest. 118:2098.
- Schreibelt, G. et al. (2012) Blood 119:2284.
- Dudziak, D. et al. (2007) Science 315:107.
- Poulin, L.F. et al. (2010) J. Exp. Med. 207:1261.
- Sancho, D. et al. (2009) Nature 458:899.
- Ahrens, S. et al. (2012) Immunity 36:635.
- Zhang, J.-G. et al. (2012) Immunity 36:646.
- Iborra, S. et al. (2012) J. Clin. Invest. 122:1628.
- Zelenay, S. et al. (2012) J. Clin. Invest. 122:1615.
Citations for Recombinant Human CLEC9a Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides
Authors: LL Eggink, KF Roby, R Cote, J Kenneth Ho
J Immunother Cancer, 2018;6(1):28.
Sample Types: Peptide
Applications: Binding Assay
Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity
Authors: T Uto, T Fukaya, H Takagi, K Arimura, T Nakamura, N Kojima, B Malissen, K Sato
Nat Commun, 2016;7(0):11273.
Sample Types: Recombinant Protein
Applications: Enzyme Assay
The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.
Authors: Iborra S, Izquierdo HM, Martinez-Lopez M, Blanco-Menendez N, Reis E Sousa C, Sancho D
J. Clin. Invest., 2012;122(5):1628-43.
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CLEC9a Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CLEC9a Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human CLEC9a Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image